DK0551401T3 - Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet - Google Patents

Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet

Info

Publication number
DK0551401T3
DK0551401T3 DK91918778.1T DK91918778T DK0551401T3 DK 0551401 T3 DK0551401 T3 DK 0551401T3 DK 91918778 T DK91918778 T DK 91918778T DK 0551401 T3 DK0551401 T3 DK 0551401T3
Authority
DK
Denmark
Prior art keywords
polypeptide
gene encoding
promoter
exogenous gene
methods
Prior art date
Application number
DK91918778.1T
Other languages
Danish (da)
English (en)
Inventor
Bert Vogelstein
Yuti Chernajovsky
Drew Pardoll
Philip Frost
Eric R Fearon
Original Assignee
Univ Texas
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24330225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0551401(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Univ Johns Hopkins filed Critical Univ Texas
Application granted granted Critical
Publication of DK0551401T3 publication Critical patent/DK0551401T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK91918778.1T 1990-09-14 1991-09-12 Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet DK0551401T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58271190A 1990-09-14 1990-09-14

Publications (1)

Publication Number Publication Date
DK0551401T3 true DK0551401T3 (da) 1996-01-22

Family

ID=24330225

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91918778.1T DK0551401T3 (da) 1990-09-14 1991-09-12 Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet

Country Status (10)

Country Link
EP (1) EP0551401B2 (ja)
JP (3) JPH06501161A (ja)
AT (1) ATE129746T1 (ja)
AU (1) AU3041295A (ja)
CA (1) CA2091346C (ja)
DE (1) DE69114299T3 (ja)
DK (1) DK0551401T3 (ja)
ES (1) ES2080341T3 (ja)
GR (1) GR3018897T3 (ja)
WO (1) WO1992005262A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (en) * 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
CA2120503C (en) * 1991-10-04 2006-04-04 Glenn Dranoff The regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
IL99821A (en) * 1991-10-22 1996-07-23 Yeda Res & Dev Antitumor vaccines comprising cells transfected with a gene encoding human il-6
DE69230506T2 (de) * 1991-10-25 2000-06-21 Sidney Kimmel Cancer Center, San Diego Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
JPH07506370A (ja) * 1992-05-01 1995-07-13 アメリカ合衆国 バイスタンダー作用による殺腫瘍療法
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
WO1994018995A1 (en) * 1993-02-17 1994-09-01 Sloan-Kettering Institute For Cancer Research Allogeneic vaccine and method to synthesize same
AU729199B2 (en) * 1993-02-22 2001-01-25 Assistance Publique - Hopitaux De Paris Composition for use in the treatment of tumours and the immunization of humans and animals
FR2699082B1 (fr) * 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
IT1261847B (it) * 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
CA2173495A1 (en) * 1993-10-06 1995-04-13 Kenneth W. Culver Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0759695B1 (en) * 1994-05-13 2006-11-08 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants, expressing the gm-csf gene
PT804210E (pt) * 1994-05-16 2003-04-30 Roche Diagnostics Gmbh Processo de imunomodelacao por transferencia adoptiva de linfocitos t citotoxicos especificos de um antigenio
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
AU711269B2 (en) * 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
DE19510344C1 (de) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Verwendung einer Tumorvakzine
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
DE69627527T2 (de) * 1995-12-28 2004-03-04 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6268214B1 (en) 1996-04-04 2001-07-31 Roche Diagnostics Gmbh Vectors encoding a modified low affinity nerve growth factor receptor
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP2001517206A (ja) 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
DK0904786T3 (da) * 1997-08-22 2005-03-21 Science Park Raf S P A Tumorvaccination under anvendelse af autologe eller HLA-relaterede antigenpræsenterende celler (APC) transduceret med et tumorantigen og et fremmed antigen, som kan fremkalde en immunreaktion
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
US9907582B1 (en) 2011-04-25 2018-03-06 Nuvasive, Inc. Minimally invasive spinal fixation system and related methods
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (en) * 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity

Also Published As

Publication number Publication date
WO1992005262A1 (en) 1992-04-02
AU659812B2 (en) 1995-06-01
DE69114299T2 (de) 1996-06-27
DE69114299T3 (de) 2005-09-15
EP0551401B2 (en) 2004-12-01
EP0551401B1 (en) 1995-11-02
AU8764391A (en) 1992-04-15
ATE129746T1 (de) 1995-11-15
EP0551401A1 (en) 1993-07-21
AU3041295A (en) 1995-11-09
JP2009165490A (ja) 2009-07-30
JP2007277265A (ja) 2007-10-25
GR3018897T3 (en) 1996-05-31
JPH06501161A (ja) 1994-02-10
CA2091346C (en) 2007-04-24
DE69114299D1 (de) 1995-12-07
ES2080341T3 (es) 1996-02-01
CA2091346A1 (en) 1992-03-15

Similar Documents

Publication Publication Date Title
DK0551401T3 (da) Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
ES2359473T3 (es) Citoquinas multifuncionales.
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
US20100074869A1 (en) Multifunctional Cytokines
AR245783A1 (es) Un procedimiento para la preparacion de un muteina del factor de necrosis tumoral humano, vector y celula hosperadora en base a la misma.
EE200300332A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
IL190068A0 (en) Dna encoding a tnf related apoptosis inducing ligand (trail) peptide and its preparation
DK305885A (da) Tumornecrosefaktor og derivater og mutantformer deraf, frem. til frems. deraf, frem. til isolering deraf fra en blanding med andre proteiner,praeparater deraf, dna som koder derfor, dna'en inkorporeret i en replicerbar vektor og celle transformeret dermed
CA2282300A1 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
AU5848090A (en) Vector-mediated genomic insertion and expression of dna in bcg
KR970705416A (ko) 종양질병 치료용 생백신(live vaccine for the treatment of tumour diseases)
CN112424361A (zh) 核酸构建体
KR970707280A (ko) 표적 t 임파구
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
CA2196416A1 (en) Recombinant herpes virus with gb gene promoter
KR100399728B1 (ko) IL-12 활성을 증가시키는 IL-12p40 소단위체돌연변이 유전자 및 이를 DNA 백신 면역증강제로이용하는 용도
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
Yingxu et al. Modulation of 17–1A antigen expression and purification of the antigen
AU2002359572A1 (en) 15603, a human ion channel family member
MX9709737A (es) Metodos para aumentar las respuestas inmunes protectoras.